The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Intellia Therapeutics is the latest CRISPR company resorting to layoffs as investors increasingly turn away from gene editing. The Cambridge, MA-based company announced Thursday that it would reduce ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

'Mad Money' host Jim Cramer weighs in on stock including: Lincoln Electric, Caesars Entertainment, CRISPR, and Seagate. This ...

What I've learned from my work in this field is that having a well-crafted commercial strategy is important for companies ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...